MaxCyte scalable electroporation: A universal cell engineering platform for development of cell-based medicines from R&D to clinic by McClure-Kuhar, Jessica et al.
MAXCYTE SCALABLE ELECTROPORATION: A UNIVERSAL CELL ENGINEERING PLATFORM FOR 
DEVELOPMENT OF CELL-BASED MEDICINES FROM R&D TO CLINIC 
 
Joseph Abad, MaxCyte, Inc. 
jabad@maxcyte.com 
Linhong Li, MaxCyte, Inc. 
Pachai Natarajan, MaxCyte, Inc. 
Madhusudan Peshwa, MaxCyte, Inc. 
Jessica Carmen, MaxCyte, Inc. 
Krista Steger, MaxCyte, Inc. 
 
 
Key Words: Lentivirus & AAV production, T-cell Engineering, CRISPR, Non-viral electroporation based 
technology 
 
Each cell-based therapeutic modality – from viral vectors to immune cell engineering and in situ gene editing – 
relies on different biologic approaches, however, they all require some type of cell engineering therapeutic 
manufacturing. MaxCyte developed a non-viral, electroporation-based cell engineering technology that has the 
performance, flexibility, safety and scalability for use in cell therapy development through to manufacturing for 
patient treatment. In this poster, we present capabilities of MaxCyte scalable electroporation, a platform of 
cGMP-compliant, CE-marked instruments with an FDA Master File. Data for high performance electroporation of 
a variety of cell types commonly used in cellular therapeutics, including adherent and suspension cells as well 
as cell lines and primary cells, are summarized. Use of MaxCyte electroporation for a breadth of real world 
applications are highlighted including lentivirus and AAV production, engineering of primary T-cells for the 
expression of an anti-mesothelin CAR molecule, and CRISPR-mediate gene editing of stem cells. These data 
will directly illustrate the scalability and consistency of MaxCyte electroporation that enables the use of this 
single cell engineering technology from early R&D to patient dosing of cell-based biotherapeutics. 
 
 
 
 
 
